Inhibition of Amyloidogenesis by Nonsteroidal Anti-inflammatory Drugs and Their Hybrid Nitrates
- 15 March 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (7) , 2293-2306
Abstract
Poor blood−brain barrier penetration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been blamed for the failure of the selective amyloid lowering agent (SALA) R-flurbiprofen in phase 3 clinical trials for Alzheimer’s disease (AD). NO-donor NSAIDs (NO-NSAIDs) provide an alternative, gastric-sparing approach to NSAID SALAs, which may improve bioavailability. NSAID analogues were studied for anti-inflammatory activity and for SALA activity in N2a neuronal cells transfected with human amyloid precursor protein (APP). Flurbiprofen (1) analogues were obtained with enhanced anti-inflammatory and antiamyloidogenic properties compared to 1, however, esterification led to elevated Aβ1−42 levels. Hybrid nitrate prodrugs possessed superior anti-inflammatory activity and reduced toxicity relative to the parent NSAIDs, including clinical candidate CHF5074. Although hybrid nitrates elevated Aβ1−42 at higher concentration, SALA activity was observed at low concentrations (≤1 μM): both Aβ1−42 and the ratio of Aβ1−42/Aβ1−40 were lowered. This biphasic SALA activity was attributed to the intact nitrate drug. For several compounds, the selective modulation of amyloidogenesis was tested using an immunoprecipitation MALDI-TOF approach. These data support the development of NO-NSAIDs as an alternative approach toward a clinically useful SALA.Keywords
This publication has 47 references indexed in Scilit:
- An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine, 2009
- NO‐flurbiprofen reduces amyloid‐β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockadeJournal of Neurochemistry, 2009
- CHF5074, a novel γ‐secretase modulator, attenuates brain β‐amyloid pathology and learning deficit in a mouse model of Alzheimer's diseaseBritish Journal of Pharmacology, 2009
- Substrate-targeting γ-secretase modulatorsNature, 2008
- In vitro and in vivo profiling of CHF5022 and CHF5074Pharmacological Research, 2007
- Alzheimer's diseaseThe Lancet, 2006
- In Vitro Metabolism of (Nitrooxy)butyl Ester Nitric Oxide-Releasing Compounds: Comparison with Glyceryl TrinitrateThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Synthesis and Biological Activity of Flurbiprofen Analogues as Selective Inhibitors of β-Amyloid1-42SecretionJournal of Medicinal Chemistry, 2005
- Inhibition of NF-kB and AP-1 activation by R- and S-flurbiprofenThe FASEB Journal, 2000
- Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomachLife Sciences, 1989